Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Shared Decision Making in Hemophilia Patient Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Rare Disease China
    Optimizing HRRm Testing and Workflow Integration in mCSPC
    Release Date:
    Review Process: Expert Review Panel
    Translation: French (link)
    Quality Improvement, Research Oncology Canada
    Driving Timely Biomarker Testing to Optimize Treatment Decisions for Colorectal Cancer Patients Across Canada
    Release Date:
    Partner: Colorectal Cancer Canada (CCC)
    Review Process: Expert Review Panel
    Translation: French (link)
    Quality Improvement, Research Oncology Canada
    Optimizing Disease Management to Improve Alopecia Areata Quality of Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Inflammation & Immunology China
    Providing Appropriate Medical Care for IBD Patients
    Release Date:
    Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)
    Review Process: Expert Review Panel
    Translation: Japanese (link)
    Quality Improvement Inflammation & Immunology Japan
    Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) Therapy
    Release Date:
    Review Process: Pfizer Internal
    Translation: French (link)
    Education Oncology Canada
    2026 Headache Medicine Fellowship - US
    Release Date:
    Review Process: Expert Review Panel
    Fellowship Internal Medicine USA
    Advances in Migraine Management
    Release Date:
    Review Process: Pfizer Internal
    Education Internal Medicine USA
    Real-World Evidence of SUL-DUR on Special Populations with CRAB Infection
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Optimizing Atopic Dermatitis Quality of Care and Best Practice at Local Level
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Inflammation & Immunology China
    Addressing HCP Knowledge Gaps in Baseline Assessments for Adults with Ulcerative Colitis Starting S1P Receptor Modulator Therapy
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Use of AI to Improve Speed/Precision of Treatment Selection & Clinical Management for Patients w/ Invasive Mold Infections
    Release Date:
    Review Process: Pfizer Internal
    Education Hospital Australia, China, France, Germany, Italy, Korea, Spain, Taiwan, United Kingdom
    Quality improvement strategies to enhance quality of life in ALK-positive lung cancer patients
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology Spain
    Maintenance Therapy in HER2+ Metastatic Breast Cancer (MBC)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Efforts to Improve Quality of Migraine Care
    Release Date:
    Partner: The Japanese Headache Society
    Review Process: Expert Review Panel
    Translation: Japanese (link)
    Quality Improvement Internal Medicine Japan
    Enhancing HCP Education in Adult Vaccination against Respiratory Infections
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines Austria, Belgium, Greece, Ireland, Luxembourg, Portugal, Switzerland
    Migraine and Women’s Health
    Release Date:
    Partner: American Headache Society
    Review Process: Expert Review Panel
    Quality Improvement, Research Internal Medicine USA
    Real World Evidence on clinical outcomes with Aztreonam-Avibactam (ATM-AVI)
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology All
    Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)
    Release Date:
    Review Process: Pfizer Internal
    Research Rare Disease USA
    Capacity Building for Clinical Trials in Sickle Cell Disease (SCD) - Education for Healthcare Professionals
    Release Date:
    Review Process: Pfizer Internal
    Education Rare Disease USA
    Prostate Cancer: Best Practices for Combining Targeted Therapies in mPC
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Transthyretin Cardiac Amyloidosis Fellowship
    Release Date:
    Review Process: Expert Review Panel
    Research Rare Disease USA
    Optimizing Adult Vaccination Ecosystem in India
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Vaccines India
    Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic Dermatitis
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA
    Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology Spain
    Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific Antibodies
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology All
    Enhancing HCP Education in Maternal Vaccination
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines Saudi Arabia
    Diagnosis and Treatment of Cancer Cachexia
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology All
    Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic Diseases
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia Areata
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    2026 Hemophilia Fellowship – United States
    Release Date:
    Review Process: Expert Review Panel
    Fellowship Rare Disease All
    Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi Arabia
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Saudi Arabia
    Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing Equity
    Release Date:
    Review Process: Expert Review Panel
    Education Inflammation & Immunology Australia
    Surveillance of Pneumococcal Disease Serotype Distribution in Pediatric and Adult Pneumococcal Disease in Türkiye
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Turkey
    Surveillance of Pneumococcal Disease Serotype Distribution in Pediatric and Adult Pneumococcal Disease in Türkiye
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Turkey
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Collaborative Community Oncology Support for Therapy Management in Relapsed/Refractory Multiple Myeloma (RRMM)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Italy, Japan, Spain, United Kingdom
    Emerging Data and Unmet Needs in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology All
    New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology All
    Education in the Era of Emerging Hemophilia Therapy (Round 2)
    Release Date:
    Review Process: Expert Review Panel
    Education Rare Disease USA
    Improving Actionable Biomarker Testing Through Technology-Enabled Solutions
    Release Date:
    Partner: Conquer Cancer, The ASCO Foundation
    Review Process: Expert Review Panel
    Quality Improvement Oncology USA
    USP <797> Pharmaceutical Compounding-Sterile Preparations: Challenges and Special Considerations
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Improving Shared Decision Making in Hemophilia: Visiting Professorship Program
    Release Date:
    Partner: Hemostasis & Thrombosis Research Society (HTRS)
    Review Process: Expert Review Panel
    Education Rare Disease USA
    Pharmacokinetics-Pharmacodynamics (PK-PD) Profile, Effectiveness and Safety of ATM-AVI in Special Populations
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Unmet Need and Emerging Data in Muscle Invasive Bladder Cancer (MIBC)
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology USA
    Bridging the Inflammatory Dermatosis Care Divide with Teledermatology
    Release Date:
    Partner: The George Washington University
    Review Process: Expert Review Panel
    Quality Improvement Inflammation & Immunology USA
    Impact of Rapid Diagnostic Tests (RDTs) on Treatment Pattern and Outcomes in Patients with Carbapenem-Resistant (CR) Pathogens
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Global Request for Proposals – Pfizer Clostridioides difficile (C. difficile) Research Collaboration
    Release Date:
    Review Process: Pfizer Internal
    Call for Collaborator(s) Vaccines France, Germany
    COLLABORATE Grant Program: Supporting Ageing Adults Living with Rare Diseases
    Release Date:
    Partner: CanAge
    Review Process: Expert Review Panel
    Education Rare Disease All
    Initiatives to Improve the Clinical Environment for Dermatologic Immunology, Inflammation, and Allergy Care
    Release Date:
    Partner: The Japanese Society for Cutaneous Immunology and Allergy
    Review Process: Expert Review Panel
    Translation: Japanese (link)
    Quality Improvement Inflammation & Immunology Japan
    Real World, Long-term Efficacy Study of Ritlecitinib in Adult and Adolescent Patients with Severe Alopecia Areata in China
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Epidemiology and surveillance of Gram-negative infections caused by carbapenemase-producing organisms (CPOs) in the UK
    Release Date:
    Review Process: Expert Review Panel
    Research Internal Medicine United Kingdom
    Advancing Care for Patients with Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC)
    Release Date:
    Partner: ALK Positive
    Review Process: Pfizer Internal
    Education Oncology All
    Quality Improvement Solutions for the Diagnosis and Management of Migraine and Headache Disorders
    Release Date:
    Partner: American Headache Society
    Review Process: Expert Review Panel
    Quality Improvement Internal Medicine Canada, USA
    Real-World Atopic Dermatitis: Italian Insights Grant
    Release Date:
    Review Process: Expert Review Panel
    Research Inflammation & Immunology Italy
    Evolving Treatment Options in First-Line Metastatic Urothelial Carcinoma (mUC) and Muscle Invasive Bladder Cancer (MIBC)
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology All
    Optimizing Care for patients with Muscle Invasive Bladder Cancer (MIBC)
    Release Date:
    Review Process: Expert Review Panel
    Translation: French (link)
    Quality Improvement Oncology Canada
    Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource Utilizatio
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Antimicrobial Stewardship —Treatment optimization under antibiotics appropriate use policy in China
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for Vitiligo
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)
    Release Date:
    Partner: American Society for Clinical Pathology (ASCP)
    Review Process: Expert Review Panel
    Quality Improvement Oncology USA
    Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factors
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement, Research Oncology Italy
    Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-T
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology USA
    2026 Inflammatory Bowel Disease (IBD) Fellowship- United States
    Release Date:
    Review Process: Expert Review Panel
    Fellowship Inflammation & Immunology USA
    Improving quality of care for patients with Relapsed/Refractory Multiple Myeloma (RRMM) treated with BCMA BsAbs
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology Italy
    Research on Long-Acting Growth Hormone
    Release Date:
    Review Process: Expert Review Panel
    Research Rare Disease All